Table 1 Characteristics of the whole population.
From: Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patients
Healthy controls n = 14 | Moderate COVID n = 10 | Severe COVID n = 11 | Critical COVID n = 16 | |
|---|---|---|---|---|
Age | 50.4 ± 13.2 | 55.5 ± 12.5 | 55.63 ± 10.5 | 62.4 ± 9.9 |
Sex | ||||
Women, n (%) | 4 (28.5) | 2 (20) | 1 (9) | 4 (25) |
Men, n (%) | 10 (71.5) | 8 (80) | 10 (91) | 12 (75) |
Hypertensive, n (%) | 0 (0) | 2 (20) | 3 (27) | 8 (50) |
Diabetes | 0 (0) | 0 (0) | 1 (9) | 5 (31) |
Smoking status | ||||
Never, n (%) | 14 (100) | 7 (70) | 10 (91) | 12 (75) |
Has stopped, n (%) | 0 | 2 (20) | 1 (9) | 4 (25) |
Current, n (%) | 0 | 1 (10) | 0 (0) | 0 (0) |
Cardiovascular history | 0 (0) | 0 (0) | 0 (0) | 3 (18.8) |
COVID-19 symptoms | NA | |||
Fever | 10 (100) | 11 (100) | 16 (100) | |
Cough | 9 (90) | 10 (90.9) | 15 (93.7) | |
Dyspnea | 10 (100) | 11 (100) | 16 (100) | |
Fatigue | 9 (90) | 11 (100) | 16 (100) | |
Myalgia | 9 (90) | 8 (72.7) | 6 (37.5) | |
Diarrhea | 4 (90) | 6 (54.5) | 1 (6.2) | |
Extent of CT lung lesions | ||||
< 10%, n (%) | 4 (40) | 0 | 0 | |
10–25%, n (%) | 4 (40) | 3 (27.3) | 3 (18.75) | |
25–50%, n (%) | 1 (10) | 8 (72.7) | 6 (37.5) | |
50–75%, n (%) | 1 (10) | 0 | 4 (25) | |
Not available | 0 | 0 | 3 (18.75) | |
Lymphocytes/mm3, mean ± SD | NA | 1198 ± 407 | 941.8 ± 320.4 | 771.3 ± 312.3 |
CRP levels (mg/L), mean ± SD | 1.2 ± 1.6 | 38.2 ± 32.5 | 170.1 ± 82.2 | 234.4 ± 123.0 |
Plasma viral load, mean ± SD | ||||
N Gene (cp/mL plasma) | NA | 325.4 ± 731.8 | 299.2 ± 239.1 | 2476 ± 6558 |
